Answer
To date, Sativex® is the only medicinal cannabis product authorised by Swissmedic in Switzerland, for add-on treatment of moderate to severe spasticity in multiple sclerosis. Also used are medicinal products exempt from authorisation, so-called magistral preparations (dronabinol, cannabis tinctures, cannabis oils, etc.), which are produced by a pharmacy to fill a medical prescription for a specific individual. Also available are products containing other cannabinoids, in particular cannabidiol (CBD), as the main active ingredient (e.g. Epidyolex®), with a total THC content below 1%, which do not fall under the Narcotics Act.